Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART

Phase 1 Terminated 19 enrolled University of Oxford Medical Research Council · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

In this study, the novel vaccine candidate, MVA.HIVconsv, will be tested for safety, tolerability and immunogenicity in HIV-1-seropositive subjects receiving effective antiretroviral therapy. MVA.HIVconsv will be tested as a single vaccine modality, as a prelude to testing in a heterologous viral vector boost regimen which will include a replication-defective simian adenovirus expressing the same immunogen.

Timeline

Start: 2009-12
Primary completion: 2013-11
Completion: 2013-11

Publications

Hancock G, Moron-Lopez S, Kopycinski J, Puertas MC, Giannoulatou E, Rose A, Salgado M, Hayton EJ, Crook A, Morgan C, Angus B, Chen F, Yang H, Martinez-Picado J, Hanke T, Dorrell L. Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects. J Int AIDS Soc. 2017 May 19;20(1):21171. doi: 10.7448/IAS.20.1.21171.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MVA.HIVconsv	Vaccine	1e+08 unknown	Intramuscular
Subject	MVA.HIVconsv	Vaccine	4e+08 unknown	Intramuscular

Indications

No indication recorded.